REPH RECRO PHARMA INC

Recro to Report Financial Results for Fourth Quarter And Year-End 2020 on February 26

Recro to Report Financial Results for Fourth Quarter And Year-End 2020 on February 26

Conference Call and Webcast Scheduled for Friday, February 26 at 4:30 p.m. Eastern Time

MALVERN, Pa., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that the company will release financial results for the fourth quarter and year-end 2020 after the market close on Friday, February 26, 2021. Recro’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Friday, February 26, 2021 to discuss the financial results and recent operational highlights.

To access the live conference call please dial (844) 243-4691 from the U.S. or (225) 283-0379 from outside the U.S. at least ten minutes prior to the start time and reference conference ID 3352999. Those interested in listening to the conference call live via webcast may do so by visiting the “Events” page in the Investor section of the Company’s website, . In addition, an archived webcast will be available on the Company’s website approximately two hours after the event and will be available for 30 days.

About Recro

Recro (NASD: ) is a revenue-generating contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.

In addition to our experience in handling DEA controlled substances and developing and manufacturing modified release oral solid dosage forms, Recro has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 120,000 square feet, in Gainesville, Georgia.

For more information about Recro’s CDMO solutions, visit .



Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
 

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
 

Ryan D. Lake (CFO)
Recro
(484) 395-2436
 
EN
19/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RECRO PHARMA INC

 PRESS RELEASE

CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc. CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. (“CoreRx”) today announced that it has completed its acquisition of Societal CDMO, Inc. (“Societal CDMO”) (Nasdaq: SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the MergerCoreRx’s tender offer to acquire all of the issued and outstanding shares of common stock (the “Shares”) of Societal CDMO, at a purchase price of $1.1...

 PRESS RELEASE

Societal CDMO Enters Into Definitive Agreement to be Acquired by CoreR...

Societal CDMO Enters Into Definitive Agreement to be Acquired by CoreRx, Inc. Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATER, Fla. and GAINESVILLE, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”) (Nasdaq: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufa...

 PRESS RELEASE

Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Prom...

Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing through Process Development and cGMP Manufacturing to Fill/Finish GAINESVILLE, Ga. and ROUND ROCK, Texas, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: ), a contract development and manufacturing organization (CDMO) de...

 PRESS RELEASE

Societal CDMO Reports Inducement Grants for New Staff

Societal CDMO Reports Inducement Grants for New Staff SAN DIEGO and GAINESVILLE, Ga., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the addition of new employees to fill open roles throughout the organization. Inducement Equity Award In connection with the hiring of these personnel, the compensation committee of Societal CDMO’s board of directors approve...

 PRESS RELEASE

Societal CDMO Reports Third Quarter 2023 Financial Results

Societal CDMO Reports Third Quarter 2023 Financial Results Recorded Q3 Revenue of $23.6 Million Signed Multiple New Business Agreements with New and Existing Customers Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million Initiated Corporate Restructuring; Expected to Result in Annualized Savings of Approximately $5.5 Million Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solvin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch